AFTER THE 20th_BEF
> RECORDINGS
> PRESENTERS
​> ATTENDEES
> INVESTORS​​​​​
> SPONSORS​​
> SUPPORTERS​

Sachs Associates would like to say we enjoyed hosting a virtual conference and thank those who participated in our 20th Annual Biotech in Europe Forum. A special thank you goes to the excellent line up of sponsors, chairpersons, panelists and presenters who made such a broad and interesting programme possible.

The virtual conference has proven to be successful in supporting our community with 650 people from 29 countries registered and nearly 1500 meetings completed so far and more planned. You can view available recordings of the sessions, which took place during the event, on our website, SachsTV YouTube channel or on Facebook, LinkedIn and Twitter profiles.

We look forward to seeing you in our future events!

SPOTLIGHT PRESENTERS INCLUDED:

PRESENTING COMPANIES INCLUDED:

---

Confirmed Keynote Speakers Included:

• “CNS Through the Haze: Tracking a Year Like No Other” by Harry Tracy, President, NI Research Inc.
• “Mobilizing a Response to COVID” by Mark Stevenson, Chief Operating Officer, Thermo Fisher Scientific
• “Thinking a Few Steps Ahead: Developing Covid Products for Beyond the Pandemic” by Peter Kolchinsky, Managing Director, RA Capital Management, LLC
• “The Miracle of VIP: How The Son of a Coptic Cleric May Rescue Humanity From COVID-19”
  by Jonathan Javitt, Chairman & CEO, NeuroRx, Inc.
• “Supporting Best-in-Class European Innovation and Tackling the Covid-19 Crisis” by Kurt Höller, Director of Business Creation, EIT Health e.V.
• Samuel Hess, Head of Economics, Canton of Basel-Stadt
• “Health-Tech Convergence: Israel Next Big Growth Engine – A New Perspective with Gulf Countries” by Laurent Choppe, Managing Partner, Cukierman & Co. Life Sciences
• “The Global Neurotech Device Market: The Emergence of Bioelectronic Medicine” by James Cavuoto, Editor & Publisher, Neurotech Reports
• More TBA...

Speakers and Chairs Included:

• Alain Vertès, Managing Director, NxR Biotechnologies GmbH
• Alberto Santagostino, SVP, Head of Cell & Gene Technologies, Lonza AG
• Alexander Breidenbach, Founder/Entrepreneur-in-Residence, KetteRx GmbH/ BB Pureos Bioventures
• Andrei Floroiu, President & CEO, Vaxart, Inc.
• Andrew Allen, Co-Founder, President & CEO, Gritstone Oncology, Inc.
• Andy Blackwell, CSO, Ieso Digital Health
• Anja König, Global Head, Novartis Venture Fund
• Anna Lisa Picciolo-Lehrke, Head Business Development Neurology, UCB Pharma
• Anne Altmeyer, Chief Business Officer, Sigilon Therapeutics, Inc.
• Achim Plum, Managing Director & CCO, SphingoTec GmbH
• Beth Shafer, Head, Neuroscience and Drug Discovery Sciences Business Development, CEI, Takeda Pharmaceuticals Co., Ltd.
• Bibhash Mukhopadhyay, Principal, New Enterprise Associates (NEA)
• Erik Buntinx, CEO, ANeuroTech
• Chandra Leo, Investment Advisor, HBM Partners AG
• Chris Maggos, Managing Director, Head of Europe, LifeSci Advisors
• Christian Jung, Partner, Dementia Discovery Fund
• Christoph Pedain, Head of Point of Care, Siemens Healthineers AG
• Corinne Venot, Senior Director, Business Development, BeiGene Ltd
• David Hallett, COO, Exscientia Ltd.
• David Gordon, Head of Investments,  Longliv Ventures, a member of CK Hutchison Holdings
• Dennis Purcell, Founder, Aisling Capital LLC
• Diana Saraceni, Co-Founder & Managing Partner, Panakès Partners SGR SpA
• Edward Littler, Founder, Collaborative Community against Coronavirus (3C)
• Edyta Jaworska, Integrated Drug Discovery Director & Management Board Member, Selvita S.A.
• Eric de La Fortelle, Venture Partner, Seventure Partners
• Erik Buntinx, Founding CEO/Inventor, ANeuroTech
• Erik Manting, CEO, DCPrime B.V.
• Esteban Pombo-Villar, CEO, TargImmune Therapeutics AG
• Filippo Petti, CEO, Celyad Oncology SA
• Florian Holzapfel, Co-Founder, Cantourage GmbH
• François Thomas, Venture Partner, Inserm Transfert Initiative / Sofimac
• Frédéric Cren, CEO, Inventiva Pharma
• Frederic Ors, CEO, IMV Inc.
• Gil Bar-Nahum, Managing Director, EMEA Head of Biotechnology, Jefferies International Ltd.
• Gilead Raday, COO, RedHill Biopharma Ltd.
• Giovanni Mariggi, Partner, Medicxi
• Guy Spigelman, EMEA Lead, Healthcare & Life Sciences Startups, Amazon Web Services EMEA SARL
• Hubert Birner, Managing Partner, TVM Life Science Management GmbH
• Holger Reithinger, General Partner, Forbion
• Isabella Schidrich, Senior Managing Director, Nasdaq
• Jakob Christian Sons, Managing Director / General Counsel, Cansativa GmbH
• Jeffrey Bockman, EVP, Head of Oncology Practice, Cello Health BioConsulting
• Jeremy Sohn, VP, Global Head of Digital Business Development & Licensing, Novartis International AG
• Joachim Vogt, Director Search & Evaluation Western Europe, AbbVie Deutschland GmbH Co. KG
• Joel Sandler, Principal, Cello Health BioConsulting
• Johan Van Hoof, Global Therapeutic Area Head of Infectious Diseases & Vaccines and Managing Director, Janssen Vaccines & Prevention B.V.
• Jordan Saxe, Global Head of Healthcare, Nasdaq
• Joy Cürten, Head of Accelerator, EIT Health e.V.
• Jürgen Gamer, VP BD, Apogenix AG
• Justyna Czyszek, Investor Services Manager, Krakowski Park Technologiczny sp. z o.o.
• Karen Wagner, Managing Partner, Ysios Capital
• Katya Smirnyagina, Executive Director, Capricorn Partners NV
• Khatereh Ahmadi, Executive Director, Oncology Search & Evaluation Lead for Europe,
• Kieran Rooney, VP, Strategic Alliances & Licensing, Amryt Pharma Plc
• Leszek Skowron, Life Science Investment Director, INNOventure Sp. z o.o.
• Lior Teitelbaum, CBO, FutuRx Ltd.
• Lubor Gaal, SVP, Head of Europe, Locust Walk
• Lynn Durham, Founder & CEO, STALICLA S.A.
• Maciek Drozdz, Advisor, Polish Center for Technology Development
• Manuel López-Figueroa, Scientific Liaison, Pritzker Neuropsychiatric Disorders Research Consortium
• Marc Lakmaaker, Founder, Clearview Capital
• Marco Baptista, VP, Research Programs, The Michael J. Fox Foundation for Parkinson's Research
• Mark Altmeyer, President & CEO, Arvelle Therapeutics
• Markus Hosang, General Partner, BioMedPartners AG
• Martin Potgeter, Vice President, Corporate Business Development, QIAGEN GmbH
• Matthias Müllenbeck, Executive Director & Head Global Licensing & BD Enabling Technologies, Merck KGaA
• Max Herrmann, Managing Director, Stifel Financial Corp.
• Melissa McCracken, Principal, Nextech Invest Ltd.
• Michael Altorfer, CEO, Swiss Biotech Association
• Michael Rice, Principal, Head of Advanced Therapeutics, Cello Health BioConsulting
• Michael Scherz, Founder & CEO, Metys Pharmaceuticals AG
• Miguel Forte, CEO, Bone Therapeutics SA
• Mike Romanos, Co-Founder & CEO, Microbiotica Ltd.
• Mike Ward, Global Head of Thought Leadership, Decision Resources, Inc.
• Murali Gopalakrishnan, Global Head, Neuroscience Search & Evaluation, AbbVie, Inc.
• Nanna Luneborg, Venture Partner, Novo Ventures
• Nathan Ajiashvili, Partner, Latham & Watkins LLP
• Nicholas Moore, Managing Director, Healthcare Investment Banking, Stifel Financial Corp.
• Nikolaas Faes, Senior Research Analyst, Bryan, Garnier & Co Ltd.
• Niels Emmerich, VP, Global Head Search & Evaluation, AbbVie, Inc.
• Nissim Darvish, Senior Managing Director, OrbiMed Advisors LLC
• Patrick Benz, Sr. Director Alliance Management, The Janssen Pharmaceutical Companies of Johnson & Johnson
• Paul Matteis, Managing Director, Co-Head of Biotech Research, Stifel Financial Corp.
• Parag Meswani, SVP, Commercial Strategy & Operations, Axovant Gene Therapies
• Peter Sandor, SVP, PFL Oncology, Astellas Pharma, Inc.
• Peter Thompson, Partner, OrbiMed Advisors LLC
• Philippe Lopes-Fernandes, SVP, Global Head of Business Development & Alliance Management, Merck
• Piotr Stępniak, Director of Immunology, ARDIGEN SA 
• Rainer Metzger, Head of Integrated Clinical Services, Medicover AB
• Rainer Strohmenger, Managing Partner, Wellington Partners
• Rao Movva, Novartis Distinguished Scientist & Independent Pharma & Biotech Advisor, Independent
• Reagan Jarvis, Co-Founder & CEO, Anocca AB
• Regina Hodits, Managing Partner, Wellington Partners
• Renee Aguiar-Lucander, CEO, Calliditas Therapeutics AB
• Richard Godfrey, CEO, BerGenBio ASA
• Richard Marsden, CEO, Synairgen Research Ltd
• Richard Ward, Director, Search and Evaluation, AstraZeneca
• Roger Bullock, Chief Medical Officer, Oryzon Genomics S.A
• Ross Muken, CFO, Click Therapeutics, Inc
• Sam Fazeli, Head of Reseach, Senior Pharmaceuticals Analyst, Bloomberg Intelligence 
• Sander van Deventer, Operating Partner, Forbion
• Scott Shandler, CEO, Longevity Biotech, Inc.
• Sebastien Petitet, CCO, Brenus Pharma
• Shafique Virani, Chief Corporate Development Officer, Recursion Pharmaceuticals
• Shayne Kennedy, Partner, Latham & Watkins LLP
• Shinichiro Fuse, Managing Director, MPM Capital, Inc.
• Sijme Zeilemaker, COO, Immunicum AB
• Silvio Belletti, Managing Director & Partner, Healthcare , Boston Consulting Group
• Sita Schubert, General Secretary, European Medical Cannabis Association (EUMCA)
• Søren Bjønness, Director – Switzerland Representative, Euronext Paris S.A.
• Søren Møller, Managing Partner, Novo Seeds, Novo Holdings A/S
• Stephanie Léouzon, Partner & Head of Europe, Torreya Partners LLP
• Steven Kelly, President & CEO, Carisma Therapeutics Inc.
• Stuart Barich, Managing Director, Raymond James
• Sumant Kulkarni, Managing Director, Biotechnology Equity Research, Canaccord Genuity LLC
• Susan Kohlhaas, Director of Research,  Alzheimer's Research UK
• Susanna Obad, Director, Business Development , F. Hoffmann-La Roche Ltd.
• Susanne Wilke, President & CEO, Cognoptix, Inc.
• Ted Fjällman, CEO, Prokarium Ltd.
• Tejinder Virk, President, Europe, Khiron Life Sciences Corp.
• Thijs Cohen Tervaert, Director, INKEF Capital BV
• Thomas Shrader, Managing Director & Healthcare Analyst, BTIG, LLC
• Tim Luker, VP, Search & Evaluation – Emerging Technology & Innovation, Corporate BD, Eli Lilly and Company
• Vanela Bushi, Director, Portfolio Strategy & Transactions, Syneos Health, LLC
• Yves Wyckmans, Senior Director Corporate & Business Development, Licensing Transactions and M&A, Actelion, a Janssen Pharmaceuticals Company of Johnson & Johnson
  

Gold Sponsor:

Silver Sponsors:

Bronze Sponsor:

​Contributing Sponsors :

---

Supported by:

---

Pharmas Attending in 2020:

---

Financial, Advisory, Investors in Attending in 2020:

AbbVie Ventures
ACXIT Capital Partners
Additio Investment Group
Advent France Biotechnology
Advent Life Sciences
Aglaia Oncology Funds 
Aisling Capital
ALSA Ventures
Alta Life Sciences
Amazon Web Services (AWS)
Aqua Partners LLC
ARCH Venture Partners
Arix Bioscience Plc. 
Arrowfield Capital
ARTO AG
Asklepios Advisors
ATAI LIfe Sciences
ATEM Capital LLC
Bavarian Capital Management
Bay City Capital LLC
BB Pureos Bioventures
Bergmann zur Hausen & Cie. GmbH
BERNINA BioInvest Ltd. 
BioGeneration Ventures
BioMedPartners AG
BioScience Managers Pty Ltd.
BioStart Consulting GmbH
Bloomberg Intelligence
Bootstrap Europe SCSP
Boston Consulting Group
Boston Financial LLC
Bpifrance

View full list